Zollinger-Ellison syndrome drives pathological gastric acid hypersecretion that must be reliably controlled — both in ongoing outpatient management and across the particular demands of the perioperative period. The structured protocol below addresses both settings.
The primary therapeutic target is suppression of gastric acid hypersecretion, with confirmation via measured gastric pH. Documented acid control is the benchmark for treatment success.
Management centres on oral proton pump inhibitor therapy to achieve sustained acid suppression, combined with a transition to intravenous acid suppression for the surgical setting. The complete regimen — specific agents, dosing, and perioperative protocol — is available in the full structured evidence-based protocol.
DOI: 10.1016/j.suc.2009.06.018